{"id":8327,"date":"2019-08-26T15:35:23","date_gmt":"2019-08-26T13:35:23","guid":{"rendered":"https:\/\/filinf.it\/?page_id=8327"},"modified":"2025-03-17T16:08:11","modified_gmt":"2025-03-17T15:08:11","slug":"indolent-lymphomas","status":"publish","type":"page","link":"https:\/\/filinf.it\/en\/structure\/scientific-commission\/indolent-lymphomas\/","title":{"rendered":"Indolent Lymphoma Commission"},"content":{"rendered":"<p><span data-contrast=\"none\"><strong>Indolent lymphomas<\/strong> include<\/span><b><span data-contrast=\"none\">\u00a0follicular<\/span><\/b><span data-contrast=\"none\">\u00a0and\u00a0<\/span><b><span data-contrast=\"none\">non-follicular<\/span><\/b><span data-contrast=\"none\">\u00a0lymphomas belonging to the group of <a href=\"https:\/\/filinf.it\/en\/about-limphomas\/non-hodgkin-lymphomas-nhl\/\">Non-Hodgkin&#8217;s Lymphomas<\/a> (a family of tumors that involve the\u00a0<\/span><b><span data-contrast=\"none\">lymphatic system<\/span><\/b><span data-contrast=\"none\">, the cells and tissues that have the task of defending the organism from external agents and diseases and guaranteeing proper circulation of fluids in the body).<br \/>\n<strong>Indolent B lymphomas<\/strong> may have an initial asymptomatic phase that does not require an immediate treatment. However, they tend to recur over the years, so they require repeated treatments.<br \/>\nThe prognosis is clearly improving, thanks above all to the new biological drugs including<\/span><span data-contrast=\"none\">, in particular, anti-<\/span><span data-contrast=\"none\">CD20 monoclonal antibodies.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><img fetchpriority=\"high\" decoding=\"async\" class=\"alignnone aligncenter\" title=\"Follicolari\" src=\"https:\/\/filinf.it\/wp-content\/uploads\/2009\/12\/Linfoma-Follicolare.png\" alt=\"Linfomi Indolenti\" width=\"875\" height=\"625\" \/><\/p>\n<p><span data-contrast=\"none\">The\u00a0<\/span><b><span data-contrast=\"none\">goals<\/span><\/b><span data-contrast=\"none\">\u00a0of the <strong>Indolent Lymphoma Commission<\/strong> are the following:<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"none\">Conduct nationwide phase III studies, also with the support of AIFA (<\/span><span data-contrast=\"none\">Agenzia<\/span><span data-contrast=\"none\">\u00a0Italiana del\u00a0<\/span><span data-contrast=\"none\">Farmaco<\/span><span data-contrast=\"none\">, Italian Drug Agency), aimed at comparing different strategies in the standard therapy of follicular lymphoma for diagnosis and relapse<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" aria-setsize=\"-1\" data-aria-posinset=\"2\" data-aria-level=\"1\"><span data-contrast=\"none\">Approve the study proposals for patients with non-follicular Indolent Lymphoma at diagnosis and disease relapse<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" aria-setsize=\"-1\" data-aria-posinset=\"2\" data-aria-level=\"1\"><span data-contrast=\"none\">Propose phase II studies with drugs or combinations of innovative drugs, in groups of patients selected for age or for specific clinical features, including asymptomatic patients<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" aria-setsize=\"-1\" data-aria-posinset=\"2\" data-aria-level=\"1\"><span data-contrast=\"none\">Approve the study proposals aimed at identifying factors of prognostic relevance to the diagnosis<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" aria-setsize=\"-1\" data-aria-posinset=\"2\" data-aria-level=\"1\"><span data-contrast=\"none\">Perform retrospective analyzes aimed at better understanding the role of some\u00a0<\/span><span data-contrast=\"none\">particular therapeutic<\/span><span data-contrast=\"none\"> practices<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" aria-setsize=\"-1\" data-aria-posinset=\"2\" data-aria-level=\"1\"><span data-contrast=\"none\">Collaborate with the Biological Studies Commission for integrated analyzes on the clinical prognostic significance of biological parameters, such as the minimal residual disease<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" aria-setsize=\"-1\" data-aria-posinset=\"2\" data-aria-level=\"1\"><span data-contrast=\"none\">Collaborate with the Imaging and Radioimmunotherapy Commission for retrospective and prospective analyzes on the prognostic significance of instrumental investigations such as PET, as well as in perspective with other FIL Commissions (Radiotherapy and Pathologists) for potential future studies,\u00a0<\/span><span data-contrast=\"none\">in particular on<\/span><span data-contrast=\"none\">\u00a0transformed or histologically more aggressive lymphomas (3b)<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" aria-setsize=\"-1\" data-aria-posinset=\"2\" data-aria-level=\"1\"><span data-contrast=\"none\">Evaluate the pathogenetic and therapeutic relevance of the association infectious agents-lymphoma in some forms of non-follicular Indolent Lymphoma<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" aria-setsize=\"-1\" data-aria-posinset=\"2\" data-aria-level=\"1\"><span data-contrast=\"none\">Interact with national and international study groups for possible collaborative studies<\/span><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Indolent lymphomas include\u00a0follicular\u00a0and\u00a0non-follicular\u00a0lymphomas belonging to the group of Non-Hodgkin&#8217;s Lymphomas (a family of tumors that involve the\u00a0lymphatic system, the cells&#8230;<\/p>\n","protected":false},"author":10007,"featured_media":0,"parent":6944,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"acf":[],"_links":{"self":[{"href":"https:\/\/filinf.it\/en\/wp-json\/wp\/v2\/pages\/8327"}],"collection":[{"href":"https:\/\/filinf.it\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/filinf.it\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/filinf.it\/en\/wp-json\/wp\/v2\/users\/10007"}],"replies":[{"embeddable":true,"href":"https:\/\/filinf.it\/en\/wp-json\/wp\/v2\/comments?post=8327"}],"version-history":[{"count":0,"href":"https:\/\/filinf.it\/en\/wp-json\/wp\/v2\/pages\/8327\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/filinf.it\/en\/wp-json\/wp\/v2\/pages\/6944"}],"wp:attachment":[{"href":"https:\/\/filinf.it\/en\/wp-json\/wp\/v2\/media?parent=8327"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}